Evaluating metastatic risk in breast cancer through CTCs and L1CAM expression
Ni Liao(Central South University), Wei Zhou(Broad Institute), Qianhui Ouyang(Central South University), Jiansheng Yi(Central South University), Chen Zeng(S.P.E.C.I.E.S.), Jingjing Chen(Central South University), Yan Huang(Fudan University), Zhouxi Chen(Zhuzhou Central Hospital), Qiong Guo, Yi Hu(Union Hospital)
Cited by 2
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156